PMID- 29323221
OWN - NLM
STAT- MEDLINE
DCOM- 20181116
LR  - 20181202
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 8
IP  - 1
DP  - 2018 Jan 11
TI  - Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic 
      Colorectal Cancer: A Meta-analysis.
PG  - 510
LID - 10.1038/s41598-017-19001-6 [doi]
LID - 510
AB  - Panitumumab and bevacizumab have been widely used in combination with 
      chemotherapy for patients with wild type RAS metastatic colorectal cancer (mCRC). 
      Whether panitumumab or bevacizumab was the optimal option remained controversial. 
      Thus, we conducted a meta-anaylsis to evaluate chemotherapy plus panitumumab 
      (C + P) versus chemotherapy plus bevacizumab (C + B) in wild type RAS mCRC. 
      Electronic databases including PubMed, Embase, and Web of Science, Cochrane 
      Library, ClinicalTrials.gov, were searched. This meta-analysis estimated the 
      progression-free survival (PFS), overall survival (OS), overall response rate 
      (ORR) and adverse events (AEs). Three randomized controlled trials with a total 
      number of 577 patients were included. In wild type RAS population, PFS [hazard 
      ratio (HR) = 0.96; 95% confidence interval (CI), 0.76 to 1.15] and OS (HR = 0.90; 
      95% CI, 0.54 to 1.27) and ORR [relative ratio (RR) = 2.06; 95% CI, 0.86 to 4.90] 
      appeared similar between the two treatments, the incidence of AEs slightly 
      increased (RR = 1.16; 95% CI 1.08 to 1.26). In conclusion, there was insufficient 
      evidence to precisely conclude that combination treatment of C + P had an 
      improved efficacy compared with C + B. Further large-scale and better-designed 
      clinical trials are still needed to evaluate the combination treatment of C + P 
      in patients with wild type RAS mCRC.
FAU - Li, Zhigui
AU  - Li Z
AD  - Department of gastrointestinal surgery, West China Hospital, Sichuan University, 
      Chengdu, Sichuan, 610041, China.
FAU - Huang, Yuqian
AU  - Huang Y
AD  - Department of gastrointestinal surgery, West China Hospital, Sichuan University, 
      Chengdu, Sichuan, 610041, China.
FAU - Zhao, Rui
AU  - Zhao R
AD  - Department of gastrointestinal surgery, West China Hospital, Sichuan University, 
      Chengdu, Sichuan, 610041, China.
FAU - Cui, Yaping
AU  - Cui Y
AD  - Department of gastrointestinal surgery, West China Hospital, Sichuan University, 
      Chengdu, Sichuan, 610041, China.
FAU - Zhou, Yong
AU  - Zhou Y
AD  - Department of gastrointestinal surgery, West China Hospital, Sichuan University, 
      Chengdu, Sichuan, 610041, China.
FAU - Wu, Xiaoting
AU  - Wu X
AD  - Department of gastrointestinal surgery, West China Hospital, Sichuan University, 
      Chengdu, Sichuan, 610041, China. wxt1@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180111
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 6A901E312A (Panitumumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bevacizumab/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy/mortality/pathology
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - Drug Therapy, Combination
MH  - Neoplasm Metastasis
MH  - Panitumumab
MH  - Proportional Hazards Models
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC5764984
COIS- The authors declare that they have no competing interests.
EDAT- 2018/01/13 06:00
MHDA- 2018/11/18 06:00
PMCR- 2018/01/11
CRDT- 2018/01/12 06:00
PHST- 2017/07/10 00:00 [received]
PHST- 2017/12/18 00:00 [accepted]
PHST- 2018/01/12 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/11/18 06:00 [medline]
PHST- 2018/01/11 00:00 [pmc-release]
AID - 10.1038/s41598-017-19001-6 [pii]
AID - 19001 [pii]
AID - 10.1038/s41598-017-19001-6 [doi]
PST - epublish
SO  - Sci Rep. 2018 Jan 11;8(1):510. doi: 10.1038/s41598-017-19001-6.